New, potent P1/P2-morpholinone-based HIV-protease inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 19, 2006, Pages 5226-5230

  Kazmierski, Wieslaw M ^a   Furfine, Eric ^a   Spaltenstein, Andrew ^a   Wright, Lois L ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Amprenavir; Aspartyl protease inhibitor; Drug; HIV; HIV 1; HIV protease inhibitor; Inhibitor; Mimetic

Indexed keywords

AMPRENAVIR; PROTEINASE INHIBITOR;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG SYNTHESIS;

CARBAMATES; HIV PROTEASE INHIBITORS; HUMANS; MOLECULAR MIMICRY; MORPHOLINES; PEPTIDES, CYCLIC; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33747584871     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.07.014     Document Type: Article

References (21)

1. Moyle G.J. Expert Opin. Invest. Drugs 7 (1998) 1313
2. Kazmierski W.M., Bevans P., Furfine E., Spaltenstein A., and Yang H. Bioorg. Med. Chem. Lett. 13 (2003) 2523
3. Kazmierski, W. M.; Bevans, P.; Furfine, E.; Porter, D.; Spaltenstein, A.; Yang, H. 223rd ACS National Meeting, Orlando, FL, United States, April 7-11, 2002, Abstract MEDI-160, 2002.
4. Spaltenstein A., Cleary D., Bock B., Kazmierski W., Furfine E., Wright L., Hazen R., Andrews W., Almond M., Tung R., and Salituro F. Bioorg. Med. Chem. Lett. 10 (2000) 1159
5. Kazmierski W.M., Andrews W., Furfine E., Spaltenstein A., and Wright L.L. Bioorg. Med. Chem. Lett. 14 (2004) 5689
6. Kazmierski W.M., Furfine E., Spaltenstein A., and Wright L.L. Bioorg. Med. Chem. Lett. 12 (2002) 3431
7. Kazmierski W.M., Furfine E., Gray-Nunez Y., Spaltenstein A., and Wright L.L. Bioorg. Med. Chem. Lett. 14 (2004) 5685
8. Kazmierski, W.; Andrews, W.; Baker, C.; Bock, B.; Cleary, D.; Furfine, E.; Gray-Nunez, Y.; Hale, M.; Hazen, R.; Salituro, F.; Schairer, W.; Spaltenstein, A.; Tung, R.; Wright, L. Book of Abstracts, 219th ACS National Meeting, San Francisco, CA, March 26-30, 2000, Abstract MEDI-126, 2000.
9. Kazmierski, W.; Furfine, E.; Spaltenstein, A.; Wright, L. In Peptides 2002, Proceedings of the European Peptide Symposium, 27th, Sorrento, Italy, August 31-September 6, 2002; Benedetti, E., Pedone, C., Eds.; pp 972-973.
10. Salituro F.G., Baker C.T., Court J.J., Deininger D.D., Kim E.E., Li B., Novak P.M., Rao B.G., Pazhanisamy S., Porter M.D., Schairer W.C., and Tung R.D. Bioorg. Med. Chem. Lett. 8 (1998) 3637
11. 1H NMR spectroscopy experiments.
12. Fritch P.C., and Kazmierski W.M. Synthesis 1 (1999) 112
13. Fritch P.C., and Kazmierski W.M. In: Kazmierski W.M. (Ed). Peptidomimetics Protocols (1998), Humana Press, Totowa, NJ 281-292
14. TenBrink R.E., Pals D.T., Harris D.W., and Johnson G.A. J. Med. Chem. 31 (1988) 671
15. Breton P., Monsigny M., and Mayer R. Int. J. Pept. Protein Res. 35 (1990) 346
16. Baker C.T., Salituro F.G., Court J.J., Deininger D.D., Kim E.E., Li B., Novak P.M., Rao B.G., Pazhanisamy S., Schairer W.C., and Tung R.D. Bioorg. Med. Chem. Lett. 8 (1998) 3631
17. Norman B.H., and Kroin J.S. Tetrahedron Lett. 36 (1995) 4151
18. Toth M.V., and Marshall G.R. Int. J. Peptide Protein Res. 36 (1990) 544
19. 3, 300 MHz) δ 7.52 (d, 2H), 7.30 (m, 5H), 6.95 (d, 2H), 4.05 (m, 1H), 3.87 (3H, s), 3.60 (m, 2H), 3.16 (m, 4H), 3.0 (m, 4H), 2.18 (1H, m), 1.97 (m, 2H), 1.60 (m, 14H), 1.23 (m, 4H).
20. 2).
21. Kim E.E., Baker C.T., Dwyer M.D., Murcko M.A., Rao B.G., Tung R.D., and Navia M.A. J. Am. Chem. Soc. 117 (1995) 1181